Korean Air seeks to raise 30 bil yen in Samurai bond sale The bond is guaranteed by KEXIM
Translated by Kim So-in 공개 2021-12-13 08:09:05
이 기사는 2021년 12월 13일 08:05 thebell 에 표출된 기사입니다.
Korean Air Lines is preparing to issue a Samurai bond, guaranteed by the Export-Import Bank of Korea (KEXIM), early next year amid ongoing trade conflicts between Korea and Japan.Korean Air has hired a foreign advisory firm to raise 30 billion yen in a Samurai bond issuance next year, with a book building process expected to take place in January 2022.
The company plans to tap the Japanese bond market to refinance existing debt as its 30 billion yen Samurai bond will mature in February 2022.
Korean Air plans to enhance its credit rating by KEXIM’s guarantee. KEXIM provided a guarantee when the airliner sold its maiden three-year Samurai bond in February 2019. It is difficult to raise funds without securing an investment grade in the conservative Japanese market. Back then, Korean Air improved its credit rating, using KEXIM’s credit rating of AA.
The Samurai bond issuance by South Korean companies has been halted since KT Corp sold its Samurai bond in 2019 due to worsening trade conflicts between Korea and Japan.
Market insiders are paying attention whether Korean Air will be able to raise funds through its planned bond sale amid ongoing conflicts between the two countries. Lotte Corp recently sold a three-year Samurai bond worth 8.5 billion yen through a private placement.
Korean Air has tried to raise funds through foreign currency-denominated bonds since last year, which all ended unsuccessfully. (Reporting by Hye-rim Pi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '적자 늘어난' GC녹십자, 혈액제제 비용 부담
- CJ ENM, 미디어사업본부 '턴어라운드 청신호' 켰다
- [Company Watch]성장 '닻' 올린 우수AMS, 하반기 현대차 부품공급 시작
- [바퀴달린 스마트폰 시대]동운아나텍의 드라이브, 현기차 이어 유럽차 탑승
- '기술평가 대신 직상장' 그리드위즈, 밸류에이션 툴 '관건'
- [Red & Blue]'소금 테마' 보라티알, 박스권 탈출 '언제쯤'
- 'FDA 품목허가 자신감' 휴젤, E타입 톡신 개발 착수
- '알렉시온 결별' 한독, 희귀질환 매출공백 메우기 총력
- 동아쏘시오, 분기 최대 매출…계열사 덕봤다
- 동아에스티, 의료파업 악재 해외·ETC로 극복